Stockscreener 앱 받기
11.95
9.33%
-1.23
시간 외 거래:
11.40
-0.55
-4.60%
전일 마감가:
$13.18
열려 있는:
$13.17
하루 거래량:
2.05M
Relative Volume:
0.53
시가총액:
$846.63M
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-5.1957
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
-13.59%
1개월 성능:
-4.55%
6개월 성능:
-75.03%
1년 성능:
-77.69%
1일 변동 폭
$11.85
$13.30
1주일 범위
$11.85
$13.90
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
11.95 | 933.77M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3%Time to Sell? - MarketBeat
(MLTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Responsive Playbooks and the MLTX Inflection - Stock Traders Daily
Why MoonLake Immunotherapeutics stock could rally in 2025Long Setup & Smart Investment Allocation Insights - Улправда
Trend Report: Will MoonLake Immunotherapeutics stock gain from strong economyWeekly Trade Analysis & Risk Managed Trade Strategies - Улправда
Will MoonLake Immunotherapeutics stock rally after Fed decisionsEarnings Beat & Free Reliable Trade Execution Plans - Улправда
Can MoonLake Immunotherapeutics stock hit analyst price targetsJuly 2025 Update & Weekly High Momentum Picks - Улправда
MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research - MSN
Is MoonLake Immunotherapeutics stock attractive for income investorsMarket Risk Analysis & Real-Time Volume Analysis Alerts - Bölüm Sonu Canavarı
MoonLake Extends Sonelokimab Data in Psoriatic Arthritis: What Investors Should Watch - TipRanks
Will MoonLake Immunotherapeutics stock reach all time highs in 2025 - DonanımHaber
Can MoonLake Immunotherapeutics stock hit record highs againWeekly Trade Summary & Risk Controlled Daily Trade Plans - DonanımHaber
Panic Selling: Will MoonLake Immunotherapeutics stock gain from strong economy2025 Momentum Check & Real-Time Price Movement Reports - Улправда
Can MoonLake Immunotherapeutics stock sustain free cash flow growth2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
How buybacks impact MoonLake Immunotherapeutics stock valueTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.7%Should You Sell? - MarketBeat
Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky Before December 15, 2025 - ACCESS Newswire
Contact Levi & Korsinsky by December 15, 2025 Deadline to - GlobeNewswire
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Invest - GuruFocus
2025-12-15 | Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025Contact Levi & Korsinsky | NDAQ:MLTX | Press Release - Stockhouse
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - marketscreener.com
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – MLTX - marketscreener.com
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX - GuruFocus
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Rutland Herald
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of MoonLake Immunotherapeutics to Contact the Firm Today! - ACCESS Newswire
2025-12-14 | Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (MLTX) Valuation After Sonelokimab Phase 3 Setback and Emerging Lawsuits - simplywall.st
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MoonLake Immunotherapeutics to Contact the Firm Today! - ACCESS Newswire
MLTX DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit - TMX Newsfile
2025-12-14 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX SECURITIES LAWSUIT: MoonLake Immunotherapeutics Investors Are Notified to Contact BFA Law Before Tomorrow's December 15 Class Action Deadline - marketscreener.com
2025-12-13 | Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6%Still a Buy? - MarketBeat
Phase 3 Miss and Fraud Suits Could Be A Game Changer For MoonLake Immunotherapeutics (MLTX) - simplywall.st
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action - GlobeNewswire
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms - GlobeNewswire Inc.
MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the - GuruFocus
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics - GlobeNewswire
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Hav - GuruFocus
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):